Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7176234 | 0.89 | HPRT1 (0.48) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL143127 | 0.89 | MTNR1A (0.46) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL3225205 | 0.87 | MTNR1A (0.45) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL3220289 | 0.85 | MTNR1A (0.44) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL11842602 | 0.85 | MTNR1A (0.44) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL7181764 | 0.83 | KDM4E (0.40) | MTNR1ANQO2DAOALDH1A1 | |
| SCHEMBL3047898 | 0.80 | CYP1A2 (0.62) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL1823898 | 0.80 | CYP1A2 (0.48) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL28097582 | 0.80 | CYP1A2 (0.48) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL1306449 | 0.80 | CYP1A2 (0.48) | MTNR1ANQO2TDP1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1028 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100040-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| WO-2021158463-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | claimed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | claimed |
| CN-102612514-B | Anti influenza agent | GRIFFITH UNIVERSITY (AU) | 2016-01-13 | — | — | CN | claimed |
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | claimed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | claimed |
| EP-2379538-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2011-10-26 | — | — | EP | claimed |
| WO-2010084402-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-29 | — | — | WO | claimed |
| EP-0417721-A2 | Novel peptidase and isomerase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-03-20 | — | — | EP | claimed |
| CN-1049016-A | New peptidase inhibitors | MERRELL DOW PHARMA (US) | 1991-02-06 | — | — | CN | claimed |
| EP-0410411-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-30 | — | — | EP | claimed |
| CN-1043504-A | The novel analogs of peptidase substrates | MERRELL DOW PHARMA (US) | 1990-07-04 | — | — | CN | claimed |
| EP-0371179-A1 | Novel analogs of peptidase substrates | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-06 | — | — | EP | claimed |
| EP-0364344-A2 | Novel peptidase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1990-04-18 | — | — | EP | claimed |
| EP-0363284-A2 | Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes | MERRELL PHARMACEUTICALS INC. (US) | 1990-04-11 | — | — | EP | claimed |
| EP-0362002-A1 | HIV protease inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | MTNR1A 2162/4885NQO2 217/4885TDP1 1718/4885 |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | MTNR1A 884/4885NQO2 447/4885TDP1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.